A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Asunercept (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors CANbridge Life Sciences
- 20 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
- 26 Sep 2016 According to a CANbridge Life Sciences media release, the first patient was dosed in the this study. Company expects to report Phase I safety data after mid-2017.
- 08 Sep 2016 Status changed from not yet recruiting to recruiting.